Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pear Vc
BioCentury | Sep 19, 2024
Finance
Series A cash for Brenus, GCTx, Nura among week’s VC highlights
Also in BioCentury’s latest Venture Report: New investment initiatives from Novo and RA Capital
BioCentury | Sep 19, 2024
Emerging Company Profile
GCTx: Simplifying iPSC-based cell therapy production
Launching with $75M, Cambridge, Mass. start-up aims to shortcut the cell therapy manufacturing process by directly activating transcription factors involved in cell fate
BioCentury | Jun 13, 2023
Management Tracks
June 13 Quick Takes: Alkermes, Sarissa trade messages ahead of proxy fight
Plus: Alladapt touts early food allergy data, Antios winds down, and updates from Gracell, Laronde, Range Bio and AZ
BioCentury | Jul 9, 2021
Emerging Company Profile
Xilis: developing miniature cancer organoids
Emerging Company Profile: Xilis raises $70M led by Mubadala to advance tech for cancer drug development, treatment selection
BioCentury | Jan 6, 2021
Finance
Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs
Biotech has aligned its internal focus on CAR NKs, but may partner elsewhere
Items per page:
1 - 5 of 5